Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 134, Issue 5, Pages 1055-1066Publisher
WILEY-BLACKWELL
DOI: 10.1002/ijc.28432
Keywords
breast cancer; PPAR gamma; mammary secretory epithelial cells; knockout mouse model; chemical carcinogenesis; chemotherapy
Categories
Funding
- Canadian Institutes of Health Research/Canadian Breast Cancer Research Alliance [84498]
- Canada Foundation for Innovation
- Ontario Ministry of Research and Innovation [10878]
- Canadian Breast Cancer Foundation (CBCF) Ontario Region [369568]
- Queen's University Breast Cancer Action Kingston
- CBCF-Ontario Region Doctoral Fellowship
- Terry Fox Foundation Training Program in Transdisciplinary Cancer Research
Ask authors/readers for more resources
Breast cancer is the leading cause of new cancer diagnoses among women. Using peroxisome proliferator-activated receptor (PPAR)((+/-)) mice, we showed normal expression of PPAR was critical to stop 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast tumorigenesis. PPAR is expressed in many breast cell types including mammary secretory epithelial (MSE) cells. MSEs proliferate as required during pregnancy, and undergo apoptosis or reversible transdifferentiation during involution once lactation is complete. Thus, MSE-specific loss of PPAR was hypothesized to enhance DMBA-mediated breast tumorigenesis. To test this, MSE cell-specific PPAR knockout (PPAR-MSE KO) and control (PPAR-WT) mice were generated, mated and allowed to nurse for three days. One week after involution, dams were treated with DMBA to initiate breast tumors, and randomized on week 7 to continue receiving a normal chow diet (DMBA Only: PPAR-WT, n = 15; PPAR-MSE KO, n = 25) or one supplemented with a PPAR activating drug (DMBA + ROSI: PPAR-WT, n = 17; PPAR-MSE KO, n = 24), and monitored for changes in breast tumor outcomes. PPAR-MSE KOs had significantly lower overall survival and decreased mammary tumor latency as compared to PPAR-WT controls. PPAR activation significantly reduced DMBA-mediated malignant mammary tumor volumes irrespective of genotype. MSE-specific PPAR loss resulted in decreased mammary gland expression of PTEN and Bax, increased superoxide anion production, and elevated serum eotaxin and RANTES, creating a protumorigenic environment. Moreover, PPAR activation in MSEs delayed mammary tumor growth in part by down-regulating Cox-1, Cox-2 and cyclin D1. Collectively, these studies highlight a protective role of MSE-specific PPAR during breast tumorigenesis, and support a novel chemotherapeutic role of PPAR activation in breast cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available